Osteoporosis Drugs Market Expected To Value US$14,786.7 Mn By 2022

According to a new market report published by Persistence Market Research “Global
Market Study on Osteoporosis Drugs: AsiaPacific to Witness Highest Growth by
2022”, the global osteoporosis drugs market is estimated to be valued at US$11,226.1
Mn by the end of 2015 and is expected to expand at a CAGR of 4.0% from 2014 to
2022, to account for US$14,786.7 Mn by 2022.
The global osteoporosis drugs market is witnessing significant growth due to rising
geriatric population and changing lifestyles impinging bone health. Prevalence of
osteoporosis is high among people aged 60 years and above. Moreover, increasing the
prevalence of osteoporosis in postmenopausal women, growing awareness about
osteoporotic care, and increasing investment in drug discovery and development are
also driving the growth of the market.
Request to view table of content @
However, there are various side effects and complications associated with
osteoporosis drugs such as heartburn, irritable bowel syndrome, nausea, and ulcers in
the stomach or esophagus. Furthermore, patent expiration of osteoporosis drugs also
inhibits the growth of the market.The osteoporosis drugs market is anticipated to
grow from an estimated US$11,226.1 Mn by the end of 2015 to account for
US$14,786.7 Mn by 2022 at a CAGR of 4.0% during the forecast period.
In North America, the prevalence of osteoporosis is high primarily due to increasing
geriatric population, growing obesity, and rising prevalence of lifestyle associated
diseases in the region. According to the National Osteoporosis Foundation, in 2013,
approximately 54 million people in the U.S. aged 50 years and above were affected
by osteoporosis and low bone mass. According to the U.S. Department of Health and
Human Services, in the U.S., approximately 250,000 hip fractures are associated with
Request Sample Report @
In Europe, increasing aging population, changing lifestyles, and increasing consumer
awareness about osteoporosis care are driving the growth of the osteoporosis drug
market. According to the International Osteoporosis Foundation, approximately 5.5
million men and 22 million women suffered from osteoporosis in 2010. Moreover,
according to International Osteoporosis Foundation, approximately 27.5 million
people in Europe suffered from osteoporosis in 2010 and the number is expected to
reach 33.9 Mn by 2030.
However, the growth of osteoporosis market in Asia Pacific is much due to rising
geriatric population and changing lifestyles in the region. Osteoporotic patients have
a higher risk of hip fractures, owing to a major cause of morbidity and mortality.
According to the International Osteoporosis Foundation, by 2050, approximately
50% of the world’s osteoporosis hip fractures would occur in women in Asia. In
addition, according to a study on Epidemiology in Osteoporosis in Japan by the
National Centre for Biotechnology Information, in 2011, approximately 15 million
people suffered from osteoporosis in Japan.
Eli Lilly and Company, F. Hoffmann-La Roche, Ltd., Merck & Co. Inc., Novartis
AG, Amgen, Inc., Actavis plc, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc.
are some of the major players of osteoporosis drugs market.
Buy Osteoporosis Drugs Market Report @
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research
model is a unique collaboration of data analytics and market research methodology to
help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a
multi-disciplinary approach. At PMR, we unite various data streams from multidimensional sources. By deploying real-time data collection, big data, and customer
experience analytics, we deliver business intelligence for organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA,Canada Toll Free: 800-961-0353
Email: [email protected]
Web: http://www.persistencemarketresearch.com